United States (Change Country)Linifanib (ABT-869) Chemical Structure
Linifanib (ABT-869) is a structurally novel, potent RTK and VEGF and PDGF receptor families inhibitor with IC50 of 0.2, 2, 4, and 7 nM for human endothelial cells, PDGFR-β, KDR, and CSF-1R, respectively. It has much less activity (IC50s > 1 μM) against unrelated RTKs, soluble tyrosine kinases, or serine/threonine kinases. In vivo ABT-869 is effective orally in the mechanism-based murine models of VEGF-induced uterine edema (ED50 = 0.5 mg/kg) and corneal angiogenesis ( >50%inhibition, 15 mg/kg ). [1][2]
[1] Mol Cancer Ther 2006;5:995-1006
[2] Mol Cancer Ther 2006;5:1007-1013
| Molecular Weight (WM): | 375.41 |
|---|---|
| Formula: | C21H18FN5O |
| Solubility(R.T.:25°C): | DMSO 75mg/mL |
| Water <1mg/mL | |
| Ethanol <1mg/mL |
A collection of 729 inhibitors
A collection of 277 kinase inhibitors
A collection of 789 FDA approved drugs
A collection of 146 natural products
A collection of 84 chemotherapeutic agents
A collection of 1484 bioactive compounds
A collection of 118 tyrosine kinase inhibitors
;J Pharmacol Exp Ther, 2012, 343(3), 617-27 Linifanib (ABT-869) purchased from Selleck
Data from [Liver Int 2011;32(3), 400-409] Linifanib (ABT-869) purchased from Selleck
;Dr. Zhang of Tianjin Medical University Linifanib (ABT-869) purchased from Selleck
Keywords:buy Linifanib (ABT-869) | Linifanib (ABT-869) supplier | purchase Linifanib (ABT-869) | Linifanib (ABT-869) cost | Linifanib (ABT-869) manufacturer | order Linifanib (ABT-869) | Linifanib (ABT-869) distributor